Jennerex lands $5.6M to advance cancer treatments

Jennerex, a developer of therapeutics for cancer patients, as well as viruses that infect cancer cells, finally closed its third round of funding at $5.6 million. The company announced its previous, $5.1 million close in mid-August. Since then, new investor Ottawa Regional Cancer Foundation also contributed.

Based in San Francisco, it says the new money will be used to push its liver cancer treatments from phase two to phase three clinical trials. It is also working on getting compounds for colorectal and lung cancer through phase one.

Jennerex has raised $25 million in private financing and $10 million in grants. Individual investors and Green Cross Corp. provided financing in previous rounds.

Next Story: Rennovia takes $6 million to turn organic feedstocks into specialty chemicals
Previous Story: Solexant plans 100 MW assembly line for solar-ink panels, looks for $50M